Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Fatemeh Chalabianloo"'
Autor:
Christer F. Aas, Jørn Henrik Vold, Fatemeh Chalabianloo, Else-Marie Løberg, Aaron G. Lim, Peter Vickerman, Kjell Arne Johansson, Lars Thore Fadnes
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-8 (2024)
Abstract People with substance use disorders (SUD) have a high prevalence of chronic hepatitis C virus (HCV) infection and mental health disorders. We aimed to assess the impact of integrated HCV treatment on psychological distress measured by Hopkin
Externí odkaz:
https://doaj.org/article/ba4229bfddac47968f2f29a8d3021973
Autor:
Jørn Henrik Vold, Anne Halmøy, Fatemeh Chalabianloo, Marianne Cook Pierron, Else-Marie Løberg, Kjell Arne Johansson, Lars Thore Fadnes
Publikováno v:
BMC Psychiatry, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Background Attention-deficit/hyperactivity disorder (ADHD) symptoms may challenge sufficient treatment of substance use and mental disorders. The literature on the extent of such symptoms among patients receiving opioid agonist therapy (OAT)
Externí odkaz:
https://doaj.org/article/63c57f954c3c4b7e809d845801a56c98
Autor:
Jørn Henrik Vold, Fatemeh Chalabianloo, Else-Marie Løberg, Christer F. Aas, Aaron G. Lim, Peter Vickerman, Kjell Arne Johansson, Lars Thore Fadnes
Publikováno v:
Substance Abuse Treatment, Prevention, and Policy, Vol 18, Iss 1, Pp 1-11 (2023)
Abstract Background Most people who inject drugs (PWIDs) suffer from severe fatigue, and chronic hepatitis C virus (HCV) infection may play a role in this. However, there is scarce evidence about interventions that alleviate fatigue among PWIDs. The
Externí odkaz:
https://doaj.org/article/66fc958e921d4256bf8dff3d3ad16e85
Autor:
Jørn Henrik Vold, Fatemeh Chalabianloo, Christer F. Aas, Else-Marie Løberg, Kjell Arne Johansson, Lars Thore Fadnes
Publikováno v:
Substance Abuse Treatment, Prevention, and Policy, Vol 16, Iss 1, Pp 1-9 (2021)
Abstract Background Continuous use of amphetamines, alcohol, benzodiazepines, cannabis, cocaine, or opioids contributes to health impairments, increased morbidity, and overdose deaths among patients with substance use disorders (SUDs). This study eva
Externí odkaz:
https://doaj.org/article/abd468f4fc2c47938308a5e47147fa1d
Autor:
Fatemeh Chalabianloo, Lars Thore Fadnes, Gudrun Høiseth, Christian Ohldieck, Jørn Henrik Vold, Christer Aas, Else-Marie Løberg, Kjell Arne Johansson, Jørgen G. Bramness
Publikováno v:
Substance Abuse Treatment, Prevention, and Policy, Vol 16, Iss 1, Pp 1-8 (2021)
Abstract Background There is little evidence-based guidance on how to optimize methadone dosages among patients with opioid addiction undergoing methadone maintenance treatment (MMT). This study aims to investigate whether self-perceived opioid withd
Externí odkaz:
https://doaj.org/article/c2d06d778a8a45f29713195055638f70
Autor:
Jørn Henrik Vold, Rolf Gjestad, Christer F. Aas, Fatemeh Chalabianloo, Svetlana Skurtveit, Else-Marie Løberg, Kjell Arne Johansson, Lars Thore Fadnes, for the INTRO-HCV Study Group
Publikováno v:
Substance Abuse Treatment, Prevention, and Policy, Vol 15, Iss 1, Pp 1-11 (2020)
Abstract Background The impact of clinical and sociodemographic factors on fatigue remains unknown among patients with substance use disorders (SUD). This study aims to evaluate fatigue among patients with SUD using a nine-item fatigue severity scale
Externí odkaz:
https://doaj.org/article/79c33c06cd8c423eb42b47bc6807d07f
Autor:
Christer F. Aas, Jørn Henrik Vold, Svetlana Skurtveit, Ingvild Odsbu, Fatemeh Chalabianloo, Aaron G. Lim, Kjell Arne Johansson, Lars Thore Fadnes
Publikováno v:
Substance Abuse Treatment, Prevention, and Policy, Vol 15, Iss 1, Pp 1-10 (2020)
Abstract Background Treatment with direct-acting antiviral agents (DAAs) offers an opportunity to eliminate hepatitis C virus (HCV) endemic among people who inject drugs (PWID) and people enrolled in opioid agonist therapy (OAT) programs. The objecti
Externí odkaz:
https://doaj.org/article/e392f5a6d51441f1aed9eed7188bc832
Autor:
Jørn Henrik Vold, Svetlana Skurtveit, Christer Aas, Fatemeh Chalabianloo, Pia Synnøve Kloster, Kjell Arne Johansson, Lars Thore Fadnes
Publikováno v:
BMC Health Services Research, Vol 20, Iss 1, Pp 1-12 (2020)
Abstract Background Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients on opioid agonist therapy (OAT) are common and have pros and cons. The objectives of the current study are to define the dispensation rates of these pot
Externí odkaz:
https://doaj.org/article/ebdac14e733c4743a2692e649d77e5fe
Autor:
Jørn Henrik Vold, Christer Aas, Svetlana Skurtveit, Ingvild Odsbu, Fatemeh Chalabianloo, Anne Halmøy, Kjell Arne Johansson, Lars Thore Fadnes
Publikováno v:
BMC Psychiatry, Vol 20, Iss 1, Pp 1-12 (2020)
Abstract Background It is estimated that up to a third of patients on opioid agonist therapy (OAT) have attention deficit hyperactivity disorder (ADHD). Treatment by ADHD medication, including a centrally acting stimulant (CAS) or atomoxetine is one
Externí odkaz:
https://doaj.org/article/ed9efb24d3aa44c7a10fc2667196622b
Autor:
Lars T. Fadnes, Christer Frode Aas, Jørn Henrik Vold, Christian Ohldieck, Rafael Alexander Leiva, Fatemeh Chalabianloo, Svetlana Skurtveit, Ole Jørgen Lygren, Olav Dalgård, Peter Vickerman, Håvard Midgard, Else-Marie Løberg, Kjell Arne Johansson, for the INTRO-HCV Study Group
Publikováno v:
BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background A large proportion of people who inject drugs (PWID) living with hepatitis C virus (HCV) infection have not been treated. It is unknown whether inclusion of HCV diagnostics and treatment into integrated substance use disorder trea
Externí odkaz:
https://doaj.org/article/f93b58bba1bd4b6d945e93e634afac23